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A
naplasticlymphoma kinase (ALK) wasﬁrstidentiﬁedas part
of the nucleophosmin (NPM)-ALK fusion protein derived
from a chromosomal translocation detected in the majority
(60%) of anaplastic large cell lymphoma (ALCL) patients.
13
Echinoderm microtubule-associated protein like 4 (EML4) was
discovered as a novel fusion partner with ALK in approximately
5% of patients with nonsmall-cell lung cancer (NSCLC).
4,5
Chromosomal translocations involving the ALK gene at 2p23
with numerous partner genes result in constitutive activation of
thekinasedomainandinan“oncogene-addicted”stateinseveral
tumors, including inﬂammatory myoﬁbroblastic tumors
(IMT),
6,7 diﬀuse large B cell lymphoma (DLBCL),
8 and squa-
mous cell carcinoma. Recently, it has also been discovered that
germline mutations in ALK are the cause of the majority of
hereditary neuroblastoma cases and that ALK activation by
mutation and/or gene ampliﬁcation is functionally relevant in
high-risk sporadic neuroblastoma.
9,10 Pharmacological studies
using the potent ALK inhibitor, 5-chloro-N
4-(2-(isopropyl-
sulfonyl)phenyl)-N
2-(2-methoxy-4-(4-(4-methylpiperazin-1-yl)-
piperidin-1-yl)phenyl)pyrimidine-2,4-diamine (1, TAE684),
have provided preclinical validation for targeting ALK kinase
activity for the treatment of NPM-ALK, EML4-ALK, and point
mutation driven ALK-dependent tumors.
1013 Altogether, these
ﬁndings suggest that development of small-molecule ALK in-
hibitors would provide eﬃcacious therapeutics for ALK-driven
hematological malignancies and solid tumors.
2
Currently, no small-molecule ALK inhibitor is approved for
clinical cancer therapy; however, a dual c-Met/ALK inhibitor
[(R)-3-(1-(2,6-dichloro-3-ﬂuorophenyl)ethoxy)-5-(1-(piperid-
in-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine, 2, PF-2341066] is
currently being investigated in a phase II/III clinical trial in
ALCL, NSCLC, and neuroblastoma.
14 To date, clinical activity
hasbeenobservedinEML4-ALKNSCLCandALK-translocated
IMT.
15,16 As compound 2 was originally developed as a c-Met
inhibitor,itscellularpotencyagainstALKisonlymoderate(IC50
∼ 200 nM), and several resistance mutations have recently been
reported.
17,18Therefore,thedevelopmentofpotentandselective
inhibitorsofwild-typeandmutantALKfortreatingALK-positive
cancersisurgentlyneeded.Inthisletter,wereportthedesignand
synthesis of 3,5-diamino-1,2,4-triazole benzyl ureas as potent
adenosine triphosphate (ATP)-competitive ALK inhibitors.
Cell-based structureactivity relationship (SAR) studies guided
the discovery of 15a, 20a, and 23a, which exhibit potent
inhibitory activity in ALK-transformed Ba/F3 cells, NPM-
ALK-positive ALCL cells, and ALK-mutated neuroblastoma
cells.
Recently, two independent groups reported the crystal struc-
tureoftheALKkinasedomainincomplexwithATPcompetitive
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ABSTRACT: A series of novel 3,5-diamino-1,2,4-triazole ben-
zyl ureas was identiﬁed as having potent anaplastic lymphoma
kinase (ALK) inhibition exempliﬁed by 15a, 20a, and 23a,
which exhibited antiproliferative IC50 values of 70, 40, and 20
nM in Tel-ALK transformed Ba/F3 cells, respectively. More-
over, 15a and 23a potently inhibited the growth and survival of
NPM-ALK positive anaplastic large cell lymphoma cell (SU-
DHL-1) and neuroblastoma cell lines (KELLY, SH-SY5Y)
containing the F1174L ALK mutation. These compounds
provide novel leads for the development of small-molecule
ALK inhibitors for cancer therapy.
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inhibitors.
19,20Todate,small-moleculeALKinhibitorshavebeen
described from the aminopyridine, pyridone, indolocarbazole,
dianilinopyrimidine, acylamino-indazole, and 1H-pyrrolo[2,3-b]-
pyrazineclasses.
2,14,21TodesignanewclassofALKinhibitor,we
explored3,5-diamino-1,2,4-triazoleureas,whichcanbeviewedas
amolecularamalgamofthe2,4-dianilinopyrimidines,suchas1,
11
and 1-acyl-1H-[1,2,4]-triazole-3,5-diamine 3
22 (Figure 1). Com-
pound 1 is a highly potent inhibitor of NPM-ALK-Ba/F3 cell
proliferation (IC50 = 3 nM). Originally, modeling studies and
subsequently cocrystal structures (PDB code: 2XB7) demon-
strated that 1 occupies the ATP-binding site and uses the
aminopyrimidine motif to form two hydrogen bonds to the
ALK“hinge”segment.
11Compound3wasdiscoveredasapotent
cyclin-dependent kinase 1 (CDK1) inhibitor with an IC50 of 4.8
nM,butwehypothesizedthatitmightexhibitaﬃnitytoALKdue
to reported modest potency (IC50 = 2.4 μM) against the highly
homologous insulin receptor kinase (InsR).
22 The chemotype 4
wasdesignedasahybridofaminopyrimidine1,aminopyridine2,
and 1,2,4-triazole-3,5-diamine 3. The 1,2,4-triazole-3,5-diamine
was used as the core scaﬀold with the potential for forming three
hydrogen bonds with the hinge segment. The acyl appendage of
4 was intended to be capable of reaching either toward the front
analogoustotheisopropylphenylsulfoneof1ortowardtheback
of the ATP binding pocket analogous to the dichlorophenyl
moiety of 2.
To validate our design strategy, a small set of 3,5-diamino-
1,2,4-triazole urea analogues representing the chemotype 4 was
synthesizedusingaconcisefour-stepsyntheticroute(Scheme1).
The ortho methoxyaniline was reacted with diphenylcyanocar-
bonimidate, and the resulting intermediate was then cyclized by
reactingwithhydrazinetogivethecorrespondingtriazole7.This
triazole was then acylated with the substituted benzylcarbamic
chlorides to yield one major regioisomer and one minor isomer.
The structures of these two regioisomeric products were as-
signed based on literature,
22 NMR spectroscopy, and the X-ray
crystallographicanalysisofarepresentativeanalogue29(Table3).
In contrast to literature reports,
22 the major regioisomer turned
out tobethe 2-acylated isomerfor themajorityof analogues that
are reported below.
The compounds 1416 were tested against Tel-ALK-Ba/F3,
EML4-ALK-Ba/F3, and parental Ba/F3 cell lines. We were
surprised by the complete lack of ALK inhibitory activity of the
1,2,4-triazole aniline urea exempliﬁed by compounds 14a and
14b. On the basis of molecular modeling and the potential for
conformationrestrictingintramolecularhydrogenbonds,wehad
anticipated that these compounds would possess some level of
ALK inhibition. However, introducing an additional one-carbon
spacer into the aniline urea side chain resulted in 1-acylated
regioisomer 15a, which possessed IC50 values of 70 and 140 nM
against Tel-ALK-Ba/F3 and EML4-ALK-Ba/F3 cell, respectively,
Figure 1. Scaﬀold design strategy.
Scheme 1
a
aReagents and conditions: (a) Diphenyl cyanocarbonimidate, THF, reﬂux. (b) Hydrazine, THF, 075  C. (c) Triphosgene, dioxane, microwave, 150
 C, 20 min. (d) Pyridine/DMF, room temperature.381 dx.doi.org/10.1021/ml200002a |ACS Med. Chem. Lett. 2011, 2, 379–384
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and was not cytotoxic to parental Ba/F3 cell (IC50 >1 0μM).
Compound 16a, possessing a two-carbon spacer in the urea side
chain, displayed 6-fold decreased Tel-ALK potency (IC50 = 450
nM). Both of the 2-acylated regio-isomers 15b and 16b were
much less potent with IC50 values of 7300 and 1900 nM,
respectively. These results indicated that proper length of the
spacer and position of acylation are the key determinants to
achieve potent ALK inhibitory activity. We reasoned that the
benzyl amine urea side chain acylated at the 1-position perhaps
provided the best ﬁt to the hydrophobic back pocket when the
central heterocyclic ring is reduced from six (as in compounds 1
and 2)t oﬁve (as in compound 4).
Encouraged by this result, a series of 3,5-diamino-1,2,4-
triazole ureas were synthesized and tested for antiproliferative
potency in Tel-ALK-Ba/F3 and EML4-ALK-Ba/F3 cells. We
ﬁrst investigated the acyl moiety of this scaﬀold by substituting
the methylsulfonylgroupat diﬀerent positions (ortho, meta, and
para) of the benzyl ring, resulting in compounds 17a19a and
17b19b. Whereas 17a maintained moderate potency against
EML4-ALK-Ba/F3 cell (IC50 = 0.61 μM), the others lost ALK
inhibitory potency substantially (Table 1). This suggested that
ortho substitution of the benzyl ring is critical for achieving
potent ALK inhibition. When 2-isopropylsulfonylbenzyl amine
was replaced with 2,6-dichlorobenzyl amine, the resulting com-
pound 20a exhibited improved potency with an IC50 of 40 nM
against Tel-ALK transformed Ba/F3 cells, but it also inhibited
parental Ba/F3 cells with an IC50 of 3.5 μM, suggesting that
additional targets were being engaged that contributed to non-
speciﬁc cytotoxicity. Interestingly, the 2-acylated product 20b
alsodisplayed inhibitory activity (IC50=480 nM) albeitwith10-
foldreducedpotency.Compound21apossessinga2,6-dichloro-
3-ﬂuoro-methylbenzyl amine side chain adopted from compound
1
23exhibitedapproximately10-folddecreasedTel-ALKpotency.
Replacement of the benzyl urea NH with an N-methyl substi-
tuent(22a)resultedinasharpdecreaseincellular potency(IC50
= 7.4 μM), suggesting that this group may be responsible for a
critical contact with the enzyme. The corresponding thio urea
compounds (23a, 23b, and 24a) exhibited potent ALK inhibi-
tory activity, but both 23b and 24a also possessed potent
nonspeciﬁc cytotoxicity toward parental Ba/F3 cells. As dis-
cussed further below, this may be related to the thio ureas
exhibiting a signiﬁcantly broadened kinase selectivity proﬁle.
Table 1. SAR of 1-Acyl Moiety for ALK
aAntiproliferative activity (IC50, μM) on Tel-Alk-Ba/F3, EML4-Alk-
Ba/F3, and parental Ba/F3, respectively; values are means of two
experiments, and the standard deviation is less than 10% of means.
bNot determined.
Table 2. SAR of Substitution on 3-Amino for ALK
aAntiproliferative activity (IC50, μM) on Tel-Alk-Ba/F3, EML4-
Alk-Ba/F3, and parental Ba/F3 respectively; values are means of two
experiments, and the standard deviation is less than 10% of means.382 dx.doi.org/10.1021/ml200002a |ACS Med. Chem. Lett. 2011, 2, 379–384
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Next, we investigated the consequence of varying the aniline
side chain at the 3-position of the 1,2,4-triazole (Table 2). Here,
wediscoveredthat2-alkyloxysubstituentontheanilinearomatic
ringservedasahandleforcontrollingkinaseselectivityasreported
for 1
11 and (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-
tetrahydropteridin-2-yl)amino)-3-methoxy-N-(1-methylpiper-
idin-4-yl)benzamide (BI-2536)
24 (see the kinase selectivity dis-
cussion).Progressingfrom2-methoxy(15a)t o2 - e t h o x y( 25a)t o
2-isoproxy(26a)resultedinagradualdecreaseincellularTel-ALK
potency. Using the aniline tail adopted from 1, compound 27a
displayed slightly decreased Tel-ALK potency (IC50 = 220 nM).
Replacement with 4-methoxycarbonyl-2-methoxy aniline and
4-bromo-2-methoxy aniline resulted in compounds 28a and 29a
withIC50valuesof520and4000nM,respectively.Thissuggested
that the 4-N-methyl piperazine functional group is important for
achievingcellularpotency.Again,onlythe1-acylatedregioisomers
exhibited cellular activity, and most of the 2-acylatedregioisomers
(15b,25b,26b,28b,and29b)we rein ac ti veexceptfo r27b,which
possessed an IC50 of 1 μM. To corroborate the structure assign-
ment, we successfully crystallized both isomers of 29a and 29b,
whichpossessaheavybromineatom.Structuralassignmentforthe
othercompoundswasmadebycomparingthe
1HNMRsignalsof
protons of the 3-amino (NH) and 5-amino (NH2) groups to the
corresponding protons of 29.
The function of the 5-amino group (NH2) was also investi-
gated in the context of the 2-(isopropylsulfonyl)benzyl and 2,
6-dichlorobenzyl compound series (Table 3). Because of the
diﬃculty of isomer separation, the 5-N-isopropyl analogues (30
and 31) and des-amino analogues (32) were tested as a mixture
of both isomers. All of the compounds displayed dramatically
reduced potency, suggesting that the 5-amino group may make
an additional hydrogen bond to the kinase hinge.
The SAR exploration of 3,5-diamino-1,2,4-triazole urea scaf-
fold revealed that the one carbon spacer of the urea side chain
(n = 1), 1-acyl substitution, and the 2-methoxy group of the
aniline side chain with N-methylpyparazine were key structural
features required to achieve potent cellular activity against Tel-
ALKandEML4-ALK.Tobetterunderstandthestructurefeature
eﬀect, we performed a molecular modeling study using Glide
25
basedupontherecentlyreportedcocrystalstructureofALKwith
1 (PDB code: 2XB7)
20 (please see the Supporting Information
for a detailed modeling study).
To evaluate the inhibitory potency of these new ALK kinase
inhibitors against diﬀerent ALK fusion and mutant ALK kinases,
themostpotentcompounds(15a,20a,and23a),aswellas1and
2,weretestedagainstapanelofcelllinesincludingNSCLC-related
cell lines
5 (EML4-ALK-Ba/F3, EML4-ALK (F1174L)-Ba/F3,
and EML4-ALK (L1196M)-Ba/F3), a NPM-ALK positive
ALCL cell line (SU-DHL-1),
26 and neuroblastoma cell lines
[KELLY (F1174L), SH-SY5Y (F1174L), and SMS-KCN
(R1275Q)] (Table 4). These selected cell lines were sensitive
to the growth inhibitory activity of 15a, 20a, and 23a but to
diﬀerent extents. This likely reﬂects a combination of kinase
selectivity proﬁles of these compounds and the degree of
addiction to ALK kinase potency in these diﬀerent cells. Com-
pounds15aand23apossessedsubmicromolarIC50valuesacross
the entire panel of cell lines with the exception of SMS-KCN
(R1275Q), which was resistant to compound 1.
With the potent antiproliferative activities of these new ALK
inhibitors in hand, we assessed the selectivity of this scaﬀold
using the KINOMEscan methodology across a panel of 402
kinases(AmbitBiosciences, SanDiego,CA).
27Five compounds,
Table 3. SAR of Substitution on 5-Amino for ALK
aAntiproliferative activity (IC50, μM) on Tel-Alk-Ba/F3, EML4-
Alk-Ba/F3, and parental Ba/F3 respectively; values are means of two
experiments, and the standard deviation is less than 10% of means.
Table 4. Antiproliferative Activity of Selected Compounds against a Diverse Panel of ALK-Positive Cell Lines
IC50 (μM)
a
cell line histology 15a 20a 23a 1 2
Tel-ALK-Ba/F3 0.07 0.04 0.02 0.001 0.19
EML4-ALK-Ba/F3 NSCLC 0.14 0.26 0.03 0.02 0.28
EML4-ALK (F1174L)-Ba/F3 NSCLC 0.72 2.1 0.29 0.06 0.62
EML4-ALK (L1196M)-Ba/F3 NSCLC 0.62 2.3 0.11 0.08 2.2
Kelly (F1174L) neuroblastoma 0.18 0.25 0.07 0.38 0.42
SH-SY5Y (F1174L) neuroblastoma 0.68 2.0 0.23 0.16 0.53
SMS-KCN (R1275Q) neuroblastoma 3.8 4.0 1.3 0.52 0.91
SU-DHL-1 (NPM-ALK) ALCL 0.01 0.08 0.001 ND
b 0.01
aThe data are expressed as the required compound concentration for inhibiting cell growth at 50%; values are means of two experiments, and the
standard deviation is less than 10% of means.
bNot determined.383 dx.doi.org/10.1021/ml200002a |ACS Med. Chem. Lett. 2011, 2, 379–384
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15a, 20a, 24a, 25a, and 26a, were screened at a concentration of
10 μM, which revealed a signiﬁcant number of potential kinase
targets for this inhibitor class (please see the Supporting In-
formation Ambit proﬁling data for details). Compound 20a has
slightly better potency than compound 15a, but 20a exhibits less
selectivity with the KINOMEscan selectivity score S10 of 0.31
(123/402) as compared to 15a with the S10 of 0.21. Similarly, as
compared to 20a, the thio urea 24a has better potency against
ALK but also possesses dramatically decreased selectivity with
the S10 of 0.62, which could be the reason for its cytotoxicity to
parental Ba/F3 cells. The 2-alkyloxy substituent on the aromatic
ring of 3-aniline side chain serves as the selectivity handle
evidenced by the S10 of 15a, 25a, and 26a, which are 0.21,
0.13, and 0.06, respectively. This is consistent with the ﬁnding
that the ortho methoxy group attached to the 2-aniline sub-
stituent in 1 oﬀering its selectivity of ALK over other tested
kinases.
11 For comparison, the 3,5-diamino-1,2,4-triazole urea
scaﬀold possesses overall improved selectivity when compared
with the 2,4-dianilinopyrimidine scaﬀold exempliﬁed by 1 [S10 =
0.66 (231/353)].
In conclusion, 15a, 20a, and 23a represent a new chemotype
capable of potent ALK inhibition. The strong inhibitory eﬀects
across a panel of clinical relevant cell lines with ALK mutation
wereobserved,suggestingthepotentialofthischemicalseriesfor
ultimately developing drugs for the treatment of diseases includ-
ing NSCLC, ALCL, and neuroblastoma. Despite the relatively
large number of kinases that can be potently targeted by this
scaﬀold, compounds like 15a, 20a, and 23a are not general
cytotoxic agents as evidenced by lack of cytotoxicity toward
parental Ba/F3 cells. Several challenges must be overcome to
further develop this chemical series including kinase selectivity,
chemical stability of the acyl triazole linkage, and synthetic
methods to produce the desired regioisomer.
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